Transcutaneous immunization and immunostimulant strategies

Immunology and Allergy Clinics of North America

Volumn 23, Issue 4, 2003, Pages 787-813

  Glenn, Gregory M ^a   Kenney, Richard T ^a   Hammond, Scott A ^a   Ellingsworth, Larry R ^a  

^a IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHOLERA TOXIN; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; RECOMBINANT ANTIGEN; TETANUS TOXOID; TRIPLE VACCINE; VACCINE;

BELL PALSY; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; HUMAN; HYDRATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; LANGERHANS CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SCAR FORMATION; STRATUM CORNEUM; VACCINATION;

EID: 0346733044     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00094-8     Document Type: Review

References (65)

1. Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv Dermatol 1999;14:209-58.
2. Yu RC, Abrams DC, Alaibac M, Chu AC. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br J Dermatol 1994;131:843-8.
3. Udey MC. Cadherins and Langerhans cell immunobiology. Clin Exp Immunol 1997;107(Suppl 1): 6-8.
4. Christoph T, Muller-Rover S, Audring H, et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol 2000;142:862-73.
5. Güereña-Burgueño F, Hall ER, Taylor DN, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002;70:1874-80.
6. Glenn GM, Taylor DN, Li X, et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000;6:1403-6.
7. Hammond SA, Tsonis C, Sellins K, et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 2000;43:45-55.
8. Yu J, Cassels F, Scharton-Kersten T, et al. Transcutaneous immunization using colonization factor and heat labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 2002;70:1056-68.
9. Roberts MS, Walker M. Water, the most natural penetration enhancer, vol 59. New York: Marcel Dekker; 1993. p. 1-30.
10. Glenn GM, Alving CR, inventors, IOMAI Corporation, assignee. Use of penetration enhancers and barrier disruption agents. US patent WO99 43350. February 25, 1999.
11. Mikszta JA, Alarcon JB, Brittingham JM, et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002;8:415-9.
12. Glenn GM, Kenney RT, Ellingsworth LR, et al. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2003;2:253-67.
13. Scharton-Kersten T, Yu J, Vassell R, et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 2000;68:5306-13.
14. Chen D, Erickson CA, Endres RL, et al. Adjuvantation of epidermal powder immunization. Vaccine 2001;19:2908-17.
15. Pilling AM, Harman RM, Jones SA, et al. The assessment of local tolerance, acute toxicity, and DNA biodistribution following particle-mediated delivery of a DNA vaccine to minipigs. Toxicol Pathol 2002;30:298-305.
16. Guebre-Xabier M, Hammond SA, Epperson DE, et al. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J Virol 2003;77:5218-25.
17. Oh YK, Kim JP, Hwang TS, et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 2001;19:4519-25.
18. Zurbriggen R, Metcalfe IC, Gluck R, Viret J-F, Moser C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines 2003;2:295-304.
19. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999;67:1100-6.
20. Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med 2003;44:570-82.
21. Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 2000;18:1847-54.
22. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 1998;391:851.
23. Glenn GM, Alving CR, inventors; The United States of America as represented by the US Army Medical Research & Material Command, assignee. Adjuvant for transcutaneous immunization. US patent 5 980 898. November 9, 1999.
24. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003;2:167-88.
25. Glenn GM, Scharton-Kersten T, Vassell R. Transcutaneous immunization. In: O'Hagen DT, editor. Vaccine adjuvants: preparation methods and research protocols (methods in molecular medicine, vol. 42). Totowa (NJ): Humana Press, Inc.; 2000. p. 315-26.
26. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995;63:1617-23.
27. Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 1999;236:215-36.
28. Gluck R, Mischler R, Durrer P, et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 2000;181:1129-32.
29. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116:804-12.
30. Snider DP. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol 1995;15:317-48.
31. Weltzin R, Guy B, Thomas Jr WD, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 2000;68:2775-82.
32. Offit PA, Hackett CJ. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 2003;111:653-9.
33. Peppoloni S, Ruggiero P, Contomi M. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003;2:285-93.
34. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine 2001;19:2701-7.
35. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 1997;158:834-41.
36. Neidleman JA, Ott G, O'Hagan D. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In: O'Hagan D, editor. Vaccine adjuvants: preparation methods and research protocols, vol 42. Totowa (NJ): Humana Press; 2000. p. 327-36.
37. Seo N, Tokura Y, Nishijima T, et al. Percutaneous peptide immunization via comeum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci U S A 2000;97:371-6.
38. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 1983;47:510-50.
39. Murphy GF, Messadi D, Fonferko E, Hancock WW. Phenotypic transformation of macrophages to Langerhans cells in the skin. Am J Pathol 1986;123:401-6.
40. El-Ghorr AA, Williams RM, Heap C, Norval M. Transcutaneous immunization with herpes simplex virus stimulates immunity in mice. FEMS Immunol Med Microbiol 2000;29:255-61.
41. Gockel CM, Bao S, Beagley KW. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol Immunol 2000;37:537-44.
42. Jakob T, Walker PS, Krieg AM, et al. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 1999;118:457-61.
43. Kremer IB, Stevens SR, Gould JW, et al. Intradermal granulocyte-macrophage colony-stimulating factor alters cutaneous antigen-presenting cells and differentially affects local versus distant immunization in humans. Clin Immunol 2000;96:29-37.
44. Vassell R, Glenn GM, Udey MC, et al. Activation of Langerhans cells following transcutaneous immunization. Presented at 5th National Symposium, Basic Aspects of Vaccines, Bethesda, MD, April 21-23, 1999.
45. Bhushan M, Cumberbatch M, Dearman RJ, et al. Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br J Dermatol 2002;146:32-40.
46. Aiba S, Katz SI. Phenotypic and functional characteristics of in vivo-activated Langerhans cells. J Immunol 1990;145:2791-6.
47. Hernando PA, Ruby JC, Halliday GM. Changes in epidermal Langerhans cells, gamma delta T cells and CD4 T cells after intradermal infection with recombinant vaccinia virus expressing cytokine genes. Immunol Cell Biol 1994;72:383-9.
48. Nagao S, Inaba S, Iijima S. Langerhans cells at the sites of vaccinia virus inoculation. Arch Dermatol Res 1976;256:23-31.
49. Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit Rev Ther Drug Carrier Syst 2001;18:503-26.
50. Kotloff KL, Sztein MB, Wasserman SS, et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001;69:3581-90.
51. Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-40.
52. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999;17:1075-81.
53. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, et al. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999;179:31-6.
54. Glenn GM, Kenney RT. Transcutaneous immunization. In: Levine MM, Kaper JB, Rappuoli R, et al, editors. New generation vaccines. New York: Marcel Dekker; in press.
55. Godefroy S, Goestch L, Plotnicky-Gilquin H, et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV). Vaccine 2003;21:1665-71.
56. Watabe S, Xin K, Ihata A, et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 2001;19:4434-44.
57. Glenn GM, Scharton-Kersten T, Vassell R, et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998;161:3211-4.
58. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 2000;18:2753-67.
59. Gebhart W, Metze D, Jurecka W. IgA in human skin appendages. In: Caputo R, editor. Immunodermatology. Rome: CIC Edizioni Internationali; 1987. p. 185.
60. Okada T, Konishi H, Ito M, Nagura H, Asai J. Identification of secretory immunoglobulin A in human sweat and sweat glands. J Invest Dermatol 1988;90:648-51.
61. Hard GC. Electron microscopic examination of Corynebacterium ovis. J Bacteriol 1969;97:1480-5.
62. Metze D, Kersten A, Jurecka W, Gebhart W. Immunoglobulins coat microorganisms of skin surface: a comparative immunohistochemical and ultrastructural study of cutaneous and oral microbial symbionts. J Invest Dermatol 1991;96:439-45.
63. Wolf MK, de Haan LA, Cassels FJ, et al. The CS6 colonization factor of human enterotoxigenic Escherichia coli contains two heterologous major subunits. FEMS Microbiol Lett 1997;148:35-42.
64. Levine MM, Ristaino P, Sack RB, et al. Colonization factor antigens I and II and type 1 somatic pili in enterotoxigenic Escherichia coli: relation to enterotoxin type. Infect Immun 1983;39:889-97.
65. Wolf M, Hall E, Taylor D, et al. Use of the human challenge model to characterize the immune response to the colonization factors of enterotoxigenic Escherichia coli (ETEC). Presented at 35th US-Japan Cholera and Other Bacterial Enteric Infections Joint Panel Meeting, Baltimore, MD, December 3-5, 1999.